<DOC>
	<DOCNO>NCT01438463</DOCNO>
	<brief_summary>The objective present study characterize dose-response relationship PURETHAL® Mites nasal provocation test order support optimal dose term clinical efficacy safety . For purpose 5 group 50 patient , suffer rhinitis rhinoconjunctivitis due House Dust Mite Allergy treat 1 year . Before start , 6 month treatment end study patient subject nasal provocation test .</brief_summary>
	<brief_title>PURETHAL® Mites Dose Range Finding Study Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Signed informed consent Patients ( male female ) must ≥ 18 ≤ 60 year screen Patients allergic rhinitis rhinoconjunctivitis least 1 year ; allergic symptom related HDM , without concomitant clinically stable control mild moderate asthma ( accord GINA classification ) Patients history concomitant asthma FEV1 &gt; 70 % inclusion . Patients without history asthma FEV1 &gt; 70 % PEF &gt; 80 % . Positive SPT HDM D. pter and/or D. far Serum specific IgEtest ( ssIgE ) level HDM D. pter D. far screen Positive nasal provocation test HDM extract screen Current clinically relevant symptom seasonal rhinitis/rhinoconjunctivitis cause allergen ( ) HDM ( demonstrate positive SPT allergen ) time inclusion Patients sensitized animal include symptomatic upon exposure regularly expose animal Completed allergenspecific immunotherapy ( SCIT SLIT ) HDM within last 5 year Completed unsuccessful allergenspecific immunotherapy ( SCIT SLIT ) within past 5 year Allergenspecific immunotherapy ( SCIT SLIT ) allergens HDM study period Any vaccination one week start therapy updosing phase Any antiIgE therapy within last 6 month prior inclusion study Severe immune disorder ( include autoimmune disease ) and/or disease require immunosuppressive drug Active malignancy malignant disease past 5 year A chronic acute disease opinion investigator might place patient additional risk , include limited following : cardiovascular insufficiency , severe unstable lung disease , endocrine disorder , clinically significant renal hepatic disease , haematological disorder Moderate severe nasal obstructive disease polyp , septal deviation etc . Clinically significant chronic sinusitis ocular infection Diseases contraindication use adrenaline ( e.g . hyperthyroidism , glaucoma ) Use systemic corticosteroid within 4 week screen Treatment systemic local bblockers Participation clinical study new investigational drug within last 3 month biological within last 6 month prior study study Pregnancy , lactation inadequate contraceptive measure ( contraceptive measure consider adequate include appropriate use oral contraception , i.m . contraception contraceptive device ) Alcohol , drug , medication abuse within past year study Any abnormal laboratory parameter screen opinion investigator consider clinically relevant Lack cooperation compliance Severe psychiatric , psychological , neurological disorder Patients employee department , 1st grade relative , partner investigator Expected change HDM exposure study ( avoidance measure , move , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>non-seasonal allergy</keyword>
	<keyword>house dust mite</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>dose response</keyword>
</DOC>